MCID: DDN006
MIFTS: 50

Duodenitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Duodenitis

MalaCards integrated aliases for Duodenitis:

Name: Duodenitis 12 54 44 15 70 32
Hemorrhagic Duodenitis 12 70
Acute Enteritis of the Mouse Intestinal Tract 70

Classifications:



External Ids:

Disease Ontology 12 DOID:8643
ICD9CM 34 535.6
MeSH 44 D004382
NCIt 50 C94409
SNOMED-CT 67 155715004
ICD10 32 K29.8
UMLS 70 C0013298 C0341245 C1522057

Summaries for Duodenitis

MalaCards based summary : Duodenitis, also known as hemorrhagic duodenitis, is related to gastrointestinal ulceration, recurrent, with dysfunctional platelets and gastritis. An important gene associated with Duodenitis is GAST (Gastrin), and among its related pathways/superpathways are T cell receptor signaling pathway and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Amoxicillin and Potassium citrate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, liver and bone, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 73 Duodenitis is inflammation of the duodenum. It may persist acutely or... more...

Related Diseases for Duodenitis

Diseases related to Duodenitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 669)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal ulceration, recurrent, with dysfunctional platelets 31.2 S100A8 GAST
2 gastritis 30.9 TNF S100A8 GAST ATP4A
3 duodenal ulcer 30.3 TNF S100A8 INS GAST CCK
4 eosinophilic gastritis 30.3 ATP4A ATP12A
5 cholecystitis 30.2 S100A8 CCK ALB
6 atrophic gastritis 30.2 TNF S100A8 GAST
7 gastric ulcer 30.2 TNF S100A8 GAST
8 granulomatous gastritis 30.1 GAST ATP4A ATP12A
9 peptic ulcer disease 30.1 TNF S100A8 GAST ATP4A ATP12A
10 gastroduodenitis 30.1 GAST CD8A CD4 ATP4A ATP12A
11 gastritis, familial giant hypertrophic 30.0 GAST ATP4A ATP12A ALB
12 duodenogastric reflux 29.8 GAST CCK ATP4A ATP12A
13 superior mesenteric artery syndrome 29.7 CRP ATP4A ATP12A
14 active peptic ulcer disease 29.7 CRP ATP4A ATP12A ALB
15 esophageal varix 29.6 INS ATP4A ATP12A ALB
16 pancreatitis 29.6 TNF INS CRP CCK
17 hyperthyroidism 29.5 INS CRP ALB
18 crohn's disease 29.4 TNF S100A8 CRP CD4 ALB
19 esophageal candidiasis 29.3 CD8A CD4 ATP4A ATP12A
20 mononeuritis multiplex 29.2 TNF CRP CD4
21 gallbladder disease 29.2 INS CRP CCK ALB
22 ileus 29.2 TNF INS CRP CCK
23 peptic ulcer perforation 29.2 S100A8 CRP ATP4A ATP12A ALB
24 obstructive jaundice 29.2 TNF CRP ALB
25 endocarditis 29.1 TNF CRP ALB
26 acute pancreatitis 29.1 TNF INS CRP CCK
27 peritonitis 29.1 TNF CRP ALB
28 gastroenteritis 29.1 TNF CRP ALB
29 irritable bowel syndrome 29.1 TNF TGM2 CRP CCK
30 aortic aneurysm, familial abdominal, 1 29.1 TNF CRP ALB
31 peptic esophagitis 29.1 TNF S100A8 GAST ATP4A ATP12A ALB
32 visceral leishmaniasis 29.1 TNF CRP ALB
33 diarrhea 29.1 TNF TGM2 GAST CCK ALB
34 cholelithiasis 29.0 INS GAST CRP CCK ALB
35 giardiasis 29.0 TOR1A TGM2 CD8A CD4 ATP4A ATP12A
36 panniculitis 29.0 TNF CRP CD8A CD4
37 end stage renal disease 29.0 TNF INS CRP ALB
38 sarcoidosis 1 28.9 TNF CRP CD8A CD4
39 intestinal tuberculosis 28.9 TNF CRP CD4 ALB
40 acquired immunodeficiency syndrome 28.9 TNF CRP CD4 ALB
41 constipation 28.8 INS GAST CRP CCK ATP4A ATP12A
42 gastroesophageal reflux 28.7 TNF S100A8 GAST CCK ATP4A ATP12A
43 myeloma, multiple 28.6 TNF CD8A CD4 ALB
44 immune deficiency disease 28.5 TNF INS CRP CD8A CD4
45 liver cirrhosis 28.4 TNF INS CRP CD8A ALB
46 lymphocytic colitis 28.4 TOR1A TNF TGM2 CD8A ATP4A ATP12A
47 dysentery 28.4 TNF CRP CD4 ATP4A ATP12A ALB
48 biliary tract disease 28.3 TNF CRP CD8A CD4 CCK ALB
49 intestinal obstruction 28.2 TNF CRP CD8A ATP4A ATP12A ALB
50 pancreatic cancer 28.0 TNF TGM2 INS GAST CD4 CCK

Comorbidity relations with Duodenitis via Phenotypic Disease Network (PDN): (show all 14)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Atrophic Gastritis
Bronchitis Chronic Kidney Disease
Deficiency Anemia Esophageal Disease
Esophagitis Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Iron Deficiency Anemia Paralytic Ileus

Graphical network of the top 20 diseases related to Duodenitis:



Diseases related to Duodenitis

Symptoms & Phenotypes for Duodenitis

MGI Mouse Phenotypes related to Duodenitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.91 ALB ATP4A CCK CD4 CD8A GAST
2 homeostasis/metabolism MP:0005376 9.9 ALB ATP12A ATP4A CCK CD4 CRP
3 digestive/alimentary MP:0005381 9.87 ALB ATP12A ATP4A CD4 GAST INS
4 immune system MP:0005387 9.73 ALB ATP4A CCK CD4 CD8A CRP
5 mortality/aging MP:0010768 9.36 ALB ATP4A CD4 CD8A GAST INS

Drugs & Therapeutics for Duodenitis

Drugs for Duodenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
2
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
6
Atorvastatin Approved Phase 4 134523-00-5 60823
7
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
8
Levodopa Approved Phase 4 59-92-7 6047
9
Pantoprazole Approved Phase 4 102625-70-7 4679
10
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435
13 Cromolyn Sodium Phase 4
14 Respiratory System Agents Phase 4
15 Antiparasitic Agents Phase 4
16 Anti-Infective Agents Phase 4
17 Antiprotozoal Agents Phase 4
18 Anti-Bacterial Agents Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Citrate Phase 4
21
Bismuth Phase 4 7440-69-9 16682734 105143
22 Anti-Infective Agents, Local Phase 4
23 Monoamine Oxidase Inhibitors Phase 4
24 Expectorants Phase 4
25 Antimalarials Phase 4
26 diuretics Phase 4
27 Dopamine Agents Phase 4
28 Antiparkinson Agents Phase 4
29 Gastrointestinal Agents Phase 4
30 Antineoplastic Agents, Hormonal Phase 4
31
Metformin Approved Phase 2, Phase 3 657-24-9 4091 14219
32
Vildagliptin Approved, Investigational Phase 2, Phase 3 274901-16-5 6918537
33
Pioglitazone Approved, Investigational Phase 2, Phase 3 111025-46-8 4829
34
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
35
Clarithromycin Approved Phase 3 81103-11-9 84029
36
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
37
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
38
Scopolamine Approved, Investigational Phase 3 51-34-3, 6533-68-2 5184
39
Esomeprazole Approved, Investigational Phase 3 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
40
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
41
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
42
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
43
Ketotifen Approved Phase 3 34580-14-8, 34580-13-7 3827
44
Rabeprazole Approved, Investigational Phase 3 117976-89-3 5029
45
Dexlansoprazole Approved, Investigational Phase 3 138530-94-6, 103577-45-3 9578005
46
Lansoprazole Approved, Investigational Phase 3 103577-45-3 3883
47
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
48
Rofecoxib Approved, Investigational, Withdrawn Phase 2, Phase 3 162011-90-7 5090
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
50
Gefarnate Investigational Phase 3 51-77-4

Interventional clinical trials:

(show top 50) (show all 236)
# Name Status NCT ID Phase Drugs
1 Therapeutic Effect of Ursodeoxycholic Acid on Duodenal Permeability and Meal Related Sensory Motor Function in Functional Dyspepsia Patients Unknown status NCT03004118 Phase 4 Placebo Oral Tablet;Ursochol oral tablet
2 The Role of Mast Cells on Duodenal Permeability After Duodenal Acid Perfusion in Healthy Volunteers Unknown status NCT02664051 Phase 4 Nalcrom;placebo
3 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
4 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
5 Endoscopic Treatment of Difficult Bile Duct Stones: Use of Direct Visualization System ("Spyglass Direct Visualization System") Associated With Electrohydraulic Lithotripsy (EHL) X Hydrostatic Balloon Dilation of the Major Duodenal Papilla Unknown status NCT02703077 Phase 4
6 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
7 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
8 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study Completed NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
9 Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin Completed NCT00331565 Phase 4
10 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
11 Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
12 Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes Mellitus (T2DM) Completed NCT00456352 Phase 4
13 Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients Completed NCT03545243 Phase 4 Pantoprazole 40mg
14 Duodenal Neuro-immune Interactions and Effects of PPI in Functional Dyspepsia Not yet recruiting NCT04713969 Phase 4 Pantoprazole 40mg
15 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Terminated NCT02032784 Phase 4 octreotide
16 Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
17 Efficacy and Safety of Autologous Bone Marrow Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus Completed NCT01759823 Phase 2, Phase 3
18 Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial. Completed NCT03223831 Phase 3
19 A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer Completed NCT01452724 Phase 3 TAK-438;Placebo;Lansoprazole;Placebo
20 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Rabeprazole-Controlled,Multicenterand Phase3 Trial in China in China Completed NCT02847455 Phase 2, Phase 3 5 mg ilaprazole;10 mg ilaprazole;10 mg Rabeprazole
21 A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection Completed NCT03050359 Phase 3 TAK-438;Lansoprazole;TAK-438 Placebo;Lansoprazole Placebo;Bismuth-Containing Quadruple Therapy
22 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial- Completed NCT01398410 Phase 2, Phase 3 Rabeprazole;Rabeprazole
23 Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial- Completed NCT01397448 Phase 2, Phase 3 E3810;E3810;Teprenone
24 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase3 Trial in China Completed NCT00952978 Phase 3 10 mg ilaprazole;20 mg omeprazole
25 Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies After Stem Cell Transplantation in T2DM Completed NCT02662400 Phase 2, Phase 3
26 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) Completed NCT01456260 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
27 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01456247 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
28 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01452763 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
29 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID). Completed NCT01452750 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
30 Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions Completed NCT00971581 Phase 3 FDC KETOPROFEN+OMEPRAZOLE
31 A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use Completed NCT01069939 Phase 3 Esomeprazole;Placebo
32 A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk Completed NCT00629928 Phase 3 Esomeprazole;Esomeprazole;Placebo
33 A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00595517 Phase 3 Esomeprazole 20 mg
34 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
35 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug Completed NCT00787254 Phase 3 Lansoprazole;Gefarnate
36 Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial Completed NCT00731198 Phase 3 Drotaverine hydrochloride;Hyoscine-N-butylbromide
37 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy Completed NCT01568398 Phase 3 TAK-438
38 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy Completed NCT01568385 Phase 3 TAK-438
39 A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00542789 Phase 3 Esomeprazole;Placebo
40 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Recruiting NCT04322604 Phase 3 lirentelimab (AK002)
41 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma (PREACT Study) Recruiting NCT03013010 Phase 3 Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
42 EUS - Guided Choledocho-duodenostomy Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Common Bile Duct Strictures. A Multi-centred Randomised Controlled Trial Recruiting NCT03000855 Phase 2, Phase 3
43 An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients With Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated With Non-steroidal Anti-inflammatory Drugs or Low-dose Aspirin Recruiting NCT03553563 Phase 3 D961H capsule 10mg;D961H sachet 10mg
44 Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
45 A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Enrolling by invitation NCT04620811 Phase 3 lirentelimab
46 A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers. Not yet recruiting NCT04215653 Phase 3 Anaprazole Sodium;Rabeprazole;Rabeprazole Placebo;Anaprazole Sodium Placebo
47 Coxib-inhibition of Duodenal Polyp Growth in Familial Adenomatous Polyposis Terminated NCT00844727 Phase 2, Phase 3 Rofecoxib;placebo
48 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin. Terminated NCT00762359 Phase 3 Lansoprazole;Gefarnate
49 Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
50 Efficacy and Safety of Exocrine Pancreatectomy With Neoprene®-Based Glue After High-risk Pancreatoduodenectomy (PD) in Patients With Pancreatic, Papilla, Duodenal, and Distal Choledochus Neoplasm Unknown status NCT03738787 Phase 2

Search NIH Clinical Center for Duodenitis

Cochrane evidence based reviews: duodenitis

Genetic Tests for Duodenitis

Anatomical Context for Duodenitis

MalaCards organs/tissues related to Duodenitis:

40
Bone Marrow, Liver, Bone, Pancreas, Small Intestine, T Cells, Heart

Publications for Duodenitis

Articles related to Duodenitis:

(show top 50) (show all 1531)
# Title Authors PMID Year
1
[Analysis of the importance of Helicobacter pylori strains in children with gastric and duodenal mucosal inflammatory changes]. 54 61
16733275 2005
2
Consensus and variable region PCR analysis of Helicobacter pylori 3' region of cagA gene in isolates from individuals with or without peptic ulcer. 54 61
11158115 2001
3
A rare case of multiple carcinoids and endocrine cell micronests in a patient with chronic duodenitis. 54 61
10964325 2000
4
Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. 61 54
9922305 1999
5
[On the pathogenesis and treatment of erosive gastritis and duodenitis]. 61 54
10380457 1999
6
[Helicobacter pylori CagA antigen antibodies]. 61 54
9748734 1998
7
Does CagA contribute to ulcer pathogenesis in a developing country, such as Sudan? 54 61
9855047 1998
8
The effects of hemodialysis on duodenal and gastric mucosal changes in uremic patients. 54 61
8738662 1996
9
The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system. 61
33074400 2021
10
Meat consumption and risk of 25 common conditions: outcome-wide analyses in 475,000 men and women in the UK Biobank study. 61
33648505 2021
11
Pancreas sparing duodenectomy in the treatment of primary duodenal neoplasms and other situations with duodenal involvement. 61
33753002 2021
12
A rare case of penetration related to ischemic duodenitis after ventricular assist device implantation for dilated cardiomyopathy. 61
33763820 2021
13
A Rare and Severe Presentation of Henoch-Schönlein Purpura in an Adolescent With Crescentic Glomerulonephritis, Arrhythmia, Acute Gastrointestinal Bleed, and Neurological Complications. 61
33796429 2021
14
Pyoderma gangrenosum and cobalamin deficiency in systemic lupus erythematosus: a rare but non fortuitous association. 61
33653418 2021
15
The Epidemiology of Annular Pancreas in the United States: A Population-based Study. 61
33769394 2021
16
Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report. 61
33625086 2021
17
Relationships between disaccharidase deficiencies, duodenal inflammation and symptom profile in children with abdominal pain. 61
33649365 2021
18
Clinical and Esophagoenteroduodenoscopy Findings in Pediatric Patients with Severe Obesity Evaluated Prior to Bariatric Surgery. 61
33633080 2021
19
Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. 61
33501492 2021
20
Ampullitis Superimposed Obstructive Jaundice in a Patient With COVID-19. 61
33737998 2021
21
Does Laparoscopic Sleeve Gastrectomy lead to Barrett's esophagus, 5-year esophagogastroduodenoscopy findings: A retrospective cohort study. 61
33643643 2021
22
[Thrombocytopenia and thromboses in a young woman]. 61
33005993 2021
23
The lymphatic system as a potential mechanism of spread of melioidosis following ingestion of Burkholderia pseudomallei. 61
33617546 2021
24
Histopathologic Manifestations of Crohn Disease in Duodenal Endoscopy Biopsy: The Value of Different Patterns of Involvement of Brunner Glands. 61
33635117 2021
25
Novel Case Report: A Previously Reported, but Pathophysiologically Unexplained, Association Between Collagenous Colitis and Protein-Losing Enteropathy May Be Explained by an Undetected Link with Collagenous Duodenitis. 61
33537921 2021
26
Vitamin D deficiency causing eosinophilic esophagogastroenteritis and ascites: a rare association. 61
33541947 2021
27
Gross and Histopathology of Goats Feeding on Opuntia stricta in Laikipia County, Kenya. 61
33623658 2021
28
Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study. 61
33440255 2021
29
Asymptomatic Duodenitis and Helicobacter pylori associated Dyspepsia in 2-Year-Old Chronic Malnourished Bangladeshi Slum-Dwelling Children: A Cross-Sectional Study. 61
33099650 2021
30
Ganglioneuroblastoma u dziecka z przewlekłym bólem brzucha ‒ opis przypadku. 61
33745248 2021
31
13C urea breath test to identify Helicobacter pylori Infection in patients with upper gastrointestinal bleeding admitted to the Emergency Department. 61
33577035 2021
32
Urinary Excretion of Iohexol as a Permeability Marker in a Mouse Model of Intestinal Inflammation: Time Course, Performance and Welfare Considerations. 61
33406796 2021
33
How is the duodenal mucosa in Functional Dyspepsia? 61
33393335 2021
34
Alterations in the histological features of the intestinal mucosa in malnourished adults of Bangladesh. 61
33504937 2021
35
Findings of Esophagogastroduodenoscopy in Patients Suspected of Upper Gastrointestinal Bleeding Referred to the Main Endoscopy Unit at King Fahad Specialist Hospital. 61
33409096 2020
36
Analysis of gastroscopy results among healthy people undergoing a medical checkup: a retrospective study. 61
33297981 2020
37
Long-term risk of dementia following hospitalization due to physical diseases: A multicohort study. 61
32886434 2020
38
Acute necrotising duodenitis. 61
33283621 2020
39
Radiation-induced damage in the upper gastrointestinal tract: clinical presentation, diagnostic tests and treatment options. 61
33317797 2020
40
Gastrointestinal Pathologies in Patients After Successful Renal Transplantation. 61
32713818 2020
41
Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. 61
33085861 2020
42
Prevalence and concordant occurrence of esophageal, gastric, duodenal, and colonic eosinophilia. 61
32666091 2020
43
RISK FACTORS AND COMORBIDITY IN DIFFERENT TYPES OF FUNCTIONAL DYSPEPSIA: RETROSPECTIVE COHORT ANALYSIS. 61
33270586 2020
44
Comparison of endoscopic and pathological findings of the upper gastrointestinal tract in transplant candidate patients undergoing hemodialysis or peritoneal dialysis treatment: a review of literature. 61
33092560 2020
45
Geographic Disparities in Clinical Characteristics of Duodenitis-Proximal Jejunitis in Horses in the United States. 61
32972682 2020
46
Mycobacterial Airsacculitis Caused by Mycobacterium fortuitum in a Southern Rockhopper Penguin (Eudyptes chrysocome). 61
33099984 2020
47
Screening Esophagogastroduodenoscopy Before Laparoscopic Sleeve Gastrectomy: Results in 819 Patients. 61
32882153 2020
48
Upper Gastrointestinal Manifestations of Inflammatory Bowel Disease. 61
32773192 2020
49
Helicobacter pylori colonisation of duodenal foveolar metaplasia requires concurrent gastric infection. 61
32934104 2020
50
Esophageal, Gastric, and Duodenal Histologic Findings in Patients with Feeding Difficulties. 61
32942680 2020

Variations for Duodenitis

Expression for Duodenitis

Search GEO for disease gene expression data for Duodenitis.

Pathways for Duodenitis

GO Terms for Duodenitis

Cellular components related to Duodenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 TNF S100A8 INS GAST CRP CD8A
2 endoplasmic reticulum lumen GO:0005788 9.46 TOR1A INS CD4 ALB
3 extracellular space GO:0005615 9.23 TNF S100A8 INS GAST CRP CCK

Biological processes related to Duodenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of inflammatory response GO:0050729 9.5 TNF TGM2 S100A8
2 regulation of protein secretion GO:0050708 9.46 TNF INS
3 sodium ion export across plasma membrane GO:0036376 9.43 ATP4A ATP12A
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.43 TNF S100A8 CCK
5 cellular potassium ion homeostasis GO:0030007 9.4 ATP4A ATP12A
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.37 ATP4A ATP12A
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.26 TNF TGM2 MALT1 CD4
8 negative regulation of lipid storage GO:0010888 9.16 TNF CRP
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 8.92 TNF S100A8 MALT1 INS

Molecular functions related to Duodenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.54 INS GAST CCK
2 protease binding GO:0002020 9.5 TNF MALT1 INS
3 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP4A ATP12A
4 identical protein binding GO:0042802 9.23 TOR1A TNF TGM2 MALT1 INS CRP
5 potassium-transporting ATPase activity GO:0008556 9.16 ATP4A ATP12A
6 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A

Sources for Duodenitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....